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Case Report
ABSTRACT
Purpose. To highlight the importance of using the Farnsworth Panel D-15 Hue test in colour vision testing in patients on ethambutol
treatment.
Case Report. A 70 year-old lady received ethambutol as part of her anti-tuberculous regime. She developed blue-yellow colour defect
detectable with the Farnsworth Panel D-15 Hue test, but not with the Isihara Pseudoisochromatic Plates. Ethambutol was immediately
discontinued from her anti-tuberculous regime. Two months later, her colour vision returned to normal.
Conclusion. This case report illustrates the importance of regular monitoring of patients receiving ethambutol for blue-yellow colour defect
using the Farnsworth Panel D-15 Hue Test.
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INTRODUCTION
Internists routinely prescribe drugs that can potentially cause
ocular toxicity. Many non-ophthalmologists use Ishihara
Pseudoisochromatic Plates (ISP) to screen for acquired colour
defects. Such use of ISP is not appropriate. The Farnsworth
Panel D-15 Hue test is rarely available outside the
ophthalmology department. In this case report, we highlight
the value of the Farnsworth Panel D-15 Hue test in the
detection of acquired blue-yellow colour defect and advocate
its use by non-ophthalmologists.
CASE REPORT
A 70-year-old lady, diagnosed of having pulmonary
tuberculosis (PTB), was started on EHRZ regime (ethambutol
15 mg/kg/day, isoniazid 5 mg/kg/day, rifampicin 10mg/kg/day
and pyrazinamide 20 mg/kg/day). She was referred to our
ophthalmology department 2 weeks after the treatment
commenced. Her renal function was normal.
On presentation, she had mild blurring of vision for the past
10 years. Otherwise there were no acute visual symptoms.
Her best corrected visual acuity (BCVA) was 6/12 in both eyes.
Colour vision test with Ishihara Pseudoisochromatic Plates
(ISP) revealed no abnormality. However, Farnsworth Panel
D-15 hue test (Figure 1) revealed asymmetrical tritanomaly
(blue-yellow colour deficiency) (Figure 2).
The Farnsworth Panel D-15 hue test was performed in day
light in front of a wide window. The caps are numbered from 1
to 15. A reference cap is fixed in the box on the patient’s left
side. The patient was first shown the normal order of the caps
in the box. Then the caps were arranged in random order by
the examiner. The test was performed first with the right eye.
The patient was asked to rearrange the caps in normal order,
step by step, starting from the reference cap. At the end of the
test, the examiner closed the lid on the caps, turned the case
up-side-down and opened it. The numbers of the caps will
then appear. The numbers were reported on the score sheets
in the order given by the patient. The test was repeated for
the left eye. The result of the test can either be a “success” or
a “failure”. For this patient, her diagram formed criss-crossed
lines according to tritan axis.
She also had mild posterior subcapsular cataract in both eyes.
Dilated pupil fundus examination showed no abnormality in
both eyes.
She was diagnosed to have bilateral acquired blue-yellow
colour deficiency secondary to ethambutol-induced optic
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neuropathy. She was immediately referred back to her chest
physician in order to discontinue the offending anti-tuberculous
medication. Two months after ethambutol discontinuation, a
repeat Farnsworth Panel D-15 hue test showed that her colour
vision returned to normal (Figure 3).
Figure 1. Farnsworth Panel D-15 hue test equipment. Different colour caps put in the black square socket; reverse side
of the socket with the discs showing the serial number from 1-15.
Figure 2. Farnsworth D-15 Hue Test at presentation showing bilateral asymmetrical tritanomaly.
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Figure 3: Farnsworth D-15 Hue Test at 2 months after discontinuation of ethambutol showing normal color vision.
DISCUSSION
Ethambutol is one of the first-line drugs for tuberculosis and
Mycobacterium avium complex (MAC) infections. Optic
neuropathy is a well documented side-effect of ethambutol.
The incidence of this reaction is proportional to the dose of
ethambutol and is observed in 15% of patients receiving 50
mg/kg per day, in 5% of patients receiving 25 mg/kg per day,
and in less than 1% of patients receiving daily doses of 15
mg/kg.1
Early-onset toxicity is an idiosyncratic reaction and is generally
irreversible while delayed-onset toxicity is dose dependent due
to zinc-chelation property of the drug and is generally
reversible. Frequently, patients who developed optic
neuropathy have no detectable risk factors.2
According to Kollner’s rule, retinal diseases cause blue-yellow
colour vision defects whereas optic nerve diseases affect red-
green discrimination.3 This distinction is however not reliable.4
Schneck et al5 demonstrated that in optic neuritis, blue-yellow
defects tend to be slightly more common in the acute phase
of the disease.
Polak et al6 reported that blue-yellow colour defects were the
commonest and earliest defect in patients with ethambutol-
induced optic neuropathy without any visual symptoms. Kumar
et al noted that all the patients in their study had blue-yellow
colour vision defects.2
Chest physicians, cardiologists, rheumatologists, urologists
and internists routinely prescribe drugs that have the potential
to cause ocular toxicity. Unfortunately, many non-
ophthalmologists especially internists use ISP to screen for
acquired colour defects. In most instances, it is the only
modality available outside the ophthalmology department to
test for colour vision abnormalities.
The ISP were designed specifically for the screening of
congenital red-green colour deficiencies. Therefore, the use
of ISP for the detection of acquired blue-yellow colour
deficiency is not appropriate. Moreover, unless a baseline ISP
test was done, the ISP is not able to differentiate congenital
from acquired red-green defects.
The Farnsworth Panel D-15 Hue test, on the other hand, is a
quick and convenient way to screen for colour vision
deficiencies. The test can be done at the bedside. It is as
easy to administer as the ISP test. It can differentiate congenital
from acquired colour vision defects. The severity of colour
defect was reflected by the number of crossing errors in the
chart.7
For congenital colour defects, the patterns of the dichotomous
analysis chart are very precise.4 In our patient, the
dichotomous analysis patterns are irregular and asymmetry.
This is characteristics for acquired colour defect, where the
eyes were affected bilaterally but with varying severity.
Subtle blue-yellow defects can only be detected with the
Lanthony Desaturated D-15 Test.8 However, there is
considerable within-subject variability in test results. Lanthony
Desaturated D-15 Test can be complicated by the wide variety
of fine colour discrimination abilities in people with normal
colour vision. Subtle loss of colour discrimination can also
occur with aging.9
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Ethambutol toxicity can occur even at the lowest recommended
dosage levels.10 Vision loss can be severe and permanent.2
Early detection and immediate therapy discontinuation are the
only effective management that can halt the progression of
vision loss and allow recovery of vision.8
In our patient the ethambutol ocular toxicity was diagnosed
by detecting blue-yellow colour defect using Farnsworth Panel
D-15 hue test, and the drug was immediately discontinued. A
repeat test after 2 months showed complete recovery of blue-
yellow colour defect. Thus, this case report illustrates the
importance of regular monitoring of patients receiving
ethambutol for blue-yellow defect using the Farnsworth Panel
D-15 hue Test.
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